Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ana Aparicio is a Professor at The University of Texas MD Anderson Cancer Center. Her research focuses on innovative applications in the treatment of metastatic prostate cancer, precision medicine in managing cardiovascular risks for patients undergoing androgen deprivation therapy, and addressing racial and ethnic disparities in cancer treatment. She has contributed to various studies exploring the dynamics of circulating tumor DNA, imaging techniques, and biomarkers in cancer management.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

John Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Efstratios Koutroumpakis

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

William Chapin

University of Pennsylvania

UNITED STATES

View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ana Aparicio

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers

MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer

The need for precision medicine in managing cardiovascular risk for men receiving ADT

Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer

18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis

Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical considerations for the management of androgen indifferent prostate cancer

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Collaborators (5)

Jianjun Zhang

John Lin

Efstratios Koutroumpakis

William Chapin

Sumit Subudhi

Make your next move.